H.C. Wainwright downgraded Hookipa Pharma (HOOK) to Neutral from Buy without a price target after the company entered into a non-binding agreement with Poolbeg for an all-stock acquisition of Poolbeg. The firm believes it would be prudent to await more clarity on the company’s path forward before projecting the cadence of potential revenue at this time.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOOK:
- Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
- Hookipa Pharma to acquire Poolbeg Pharma
- Hookipa Pharma downgraded to Sector Perform from Outperform at RBC Capital
- Hookipa Pharma price target lowered to $7 from $24 at JMP Securities
- Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program